MUNICH, Germany & IRVINE, Calif.--(BUSINESS WIRE)--JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of next generation transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, today announced the appointment of medical device veteran and JenaValve Chairman of the Board, Jan Keltjens, as Interim Chief Executive Officer and Executive Chairman. He replaces David J. Drachman, who has resigned from the company for non-business related personal reasons. Mr. Keltjens will assume the role effective immediately and until a permanent replacement for Mr. Drachman has been hired.
Mr. Keltjens has a strong track record in the medical device sector and more than 30 years of management experience. In addition to his position as Chairman of the Board of JenaValve which he was appointed to in October 2014, he currently holds a number of non-executive Board roles. He most recently served as chief executive officer of Sapiens Steering Brain Stimulation (acquired by Medtronic in August 2014).
“I would like to thank Dave Drachman for his many valuable contributions to JenaValve over the past six months. It is unfortunate that his personal circumstances led him to resign his position. We sincerely wish Dave all the best for his future. As Interim CEO, I will work closely with the leadership team to ensure that we maintain momentum and continue to drive our Company forward while we search for a new US-based Chief Executive,” said Mr. Keltjens. “In the past six months, we have made great progress in finalizing the design and testing of our next generation pericardial valve platform. Moreover, we have worked closely with the regulatory agencies in both the US and the European Union to define clear clinical and regulatory pathways. I am confident in our future based on great technology, strong teams in Munich and Irvine and the TAVI market being one of the fastest growth opportunities in medical devices as well as unwavering support from our Board and shareholders.”
JenaValve Technology, Inc., based in Munich, Germany and Irvine, California, develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked for aortic valve stenosis as well as for the unique indication to treat patients suffering from aortic valve insufficiency. JenaValve currently markets in Europe and other selected markets worldwide. The Company’s new transfemoral TAVI system is expected to gain CE Mark in 2016. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.
Additional information is available at www.jenavalve.com.